SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?


To: Braddock Bull who wrote (2571)2/27/1998 1:52:00 AM
From: Linda Kaplan  Respond to of 7041
 
Brad,

Why would shorts cover now? The article damned Zonagen on every possible level and gives little hope for the company. When Viagra is approved, Zonagen will surely be hurt. I can only assume that the only buyers now are those who are uninformed, misinformed or personally invested in shoring up the company (work for the company, perhaps).

We all hate to admit we were wrong. I admit to having held LIPO for ages after it went from 25 to 8 (in a day) and then drifted down to 5. I kept hoping for a revival, against medical advice!! My friend hounded me to dump it saying it had nothing to give it new life, but I stubbornly held on. Similarly, other stocks. So I can understand people hoping that the company is better than it sounds.

Still, if they can get 19 for Zonagen now, isn't that better than waiting till it halves in value from here? I'm surely not saying it will, (how could I know?) but in my experience with stocks of this kind, once they clearly don't have a product, or don't have a product viewed as successful, the value of the stocks drops markedly.

Look at VVUS, which has a successful product, and did it without advertising! I paid 35 for VVUS and it's 11-12 now. What hit VVUS? Viagra is one of the two things that decimated VVUS in my opinion. Zonagen is prone to the same or worse Viagra flu as VVUS, isn't it?

Linda



To: Braddock Bull who wrote (2571)2/27/1998 6:07:00 PM
From: Claud B  Read Replies (1) | Respond to of 7041
 
<< I would be shocked
if they allowed their authors to hold prior positions in stocks that are the subject of
articles.>>

Don't be shocked. Arthur Leavitt (SEC Chairman) just today addressed
this growing problem in the industry.

Claud